16.07.2025 • News

Covestro Extends Contract with CTO Thorsten Dreier Until 2031

Thorsten Dreier will remain Covestro's Chief Technology Officer for another five years. The Supervisory Board has extended his contract until June 30, 2031.

Thorsten Dreier
Thorsten Dreier, Chief Technology Officer, Covestro
© Covestro

Dreier has been Chief Technology Officer and a member of the Covestro Board of Management since July 2023 and Labor Director since September 2023.

"Thorsten Dreier has significantly advanced Covestro's transition to climate-neutral production over the past two years, making an important contribution to Covestro's vision of a circular economy,” said Richard Pott, Chair of the Supervisory Board of Covestro AG. “We are convinced that Mr. Dreier will successfully continue the transformation of Covestro and we look forward to our continued collaboration."

"I am grateful for the trust placed in me. I am looking very much forward to continuing to drive the transformation of our company together with the Covestro employees and the Board of Management," said Dreier. “As Labor Director, it is very important to me to continue the trusting and constructive collaboration with the employees and the employee representatives that I have been able to establish in the past years."

In his role as Chief Technology Officer, Dreier is responsible for the corporate functions of Engineering, Process Technology, Group Health, Safety, Environment & Reliability, and Group Procurement. He is also responsible for the Performance Materials reporting segment.

Other members of Covestro's five-member Board of Management are CEO Markus Steilemann, Christian Baier as Chief Financial Officer, Sucheta Govil as Chief Sales and Marketing Officer, and Monique Buch, who will succeed Sucheta Govil as Chief Sales and Marketing Officer from August 2025.

Company

Logo:

Covestro


51368 Leverkusen
Germany

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.